Peapack Gladstone Financial Corp Purchases 88 Shares of Cencora, Inc. (NYSE:COR)

Peapack Gladstone Financial Corp lifted its holdings in Cencora, Inc. (NYSE:COR) by 2.8% during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,240 shares of the company’s stock after buying an additional 88 shares during the period. Peapack Gladstone Financial Corp’s holdings in Cencora were worth $729,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. Pacer Advisors Inc. lifted its holdings in Cencora by 6,855.3% during the third quarter. Pacer Advisors Inc. now owns 2,065,374 shares of the company’s stock worth $464,874,000 after acquiring an additional 2,035,679 shares during the period. Bank of Montreal Can increased its position in shares of Cencora by 136.8% during the 2nd quarter. Bank of Montreal Can now owns 641,887 shares of the company’s stock valued at $153,623,000 after purchasing an additional 370,841 shares during the last quarter. American Century Companies Inc. raised its stake in shares of Cencora by 155.0% during the 2nd quarter. American Century Companies Inc. now owns 598,438 shares of the company’s stock worth $134,828,000 after purchasing an additional 363,796 shares during the period. Wellington Management Group LLP boosted its holdings in shares of Cencora by 7.0% in the 3rd quarter. Wellington Management Group LLP now owns 5,193,386 shares of the company’s stock worth $1,168,927,000 after buying an additional 338,452 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its holdings in shares of Cencora by 21.7% in the 3rd quarter. Two Sigma Advisers LP now owns 1,638,400 shares of the company’s stock worth $368,771,000 after buying an additional 292,600 shares during the last quarter. 97.52% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several analysts have commented on the stock. JPMorgan Chase & Co. lifted their price objective on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 21st. Bank of America reaffirmed a “neutral” rating and issued a $245.00 price target (down previously from $275.00) on shares of Cencora in a report on Wednesday, September 18th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Wells Fargo & Company decreased their target price on Cencora from $249.00 to $237.00 and set an “equal weight” rating for the company in a research report on Friday. Finally, Leerink Partners lowered their target price on Cencora from $277.00 to $275.00 and set an “outperform” rating on the stock in a research note on Monday, October 7th. Two analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. Based on data from MarketBeat.com, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 21,509 shares of the business’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total transaction of $5,208,619.44. Following the completion of the transaction, the chairman now directly owns 306,752 shares in the company, valued at $74,283,064.32. The trade was a 6.55 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In the last quarter, insiders have sold 93,018 shares of company stock valued at $22,478,942. Corporate insiders own 15.80% of the company’s stock.

Cencora Trading Up 0.1 %

NYSE:COR opened at $232.24 on Monday. Cencora, Inc. has a 1 year low of $195.83 and a 1 year high of $253.27. The stock’s fifty day moving average price is $238.36 and its two-hundred day moving average price is $234.14. The company has a debt-to-equity ratio of 4.84, a current ratio of 0.88 and a quick ratio of 0.53. The company has a market cap of $44.89 billion, a P/E ratio of 30.92, a P/E/G ratio of 1.54 and a beta of 0.45.

Cencora Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Investors of record on Friday, November 15th were issued a dividend of $0.55 per share. This is a boost from Cencora’s previous quarterly dividend of $0.51. The ex-dividend date was Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.95%. Cencora’s dividend payout ratio is 29.29%.

Cencora Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.